Therapeutic effect of micafungin on oropharyngeal candidiasis in congenitally immunodeficient mice

Japanese Journal of Chemotherapy

Volumn 50, Issue SUPPL. 1, 2002, Pages 48-53

  Nakai, Toru ^a   Hatano, Kazuo ^a   Ikeda, Fumiaki ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; MICAFUNGIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CELL INFILTRATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; ERADICATION THERAPY; FUNGAL CELL; FUNGUS HYPHAE; HISTOPATHOLOGY; IMMUNE DEFICIENCY; INCIDENCE; INFLAMMATORY CELL; INOCULATION; KERATINIZATION; MORPHOLOGY; MOUSE; MOUSE STRAIN; MOUTH MUCOSA; NONHUMAN; RELAPSE; THRUSH; TONGUE; TREATMENT OUTCOME;

EID: 0036920438     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Japanese source. No.24: p.342-344, 1999
2. Pons V, Greenspan D, Lozada-Nur F, et al.: Oropharyngeal candidiasis in patients with AIDS: Randomized comparison of fluconazole versus nystatin oral suspension. Clin Infect Dis 24: 1204-1207, 1997
3. USPHS/IDSA Prevention of Opportunistic Infections Working Group: Preface to the 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodefiency virus. Clin Infect Dis 25 (Suppl 3): S 299-312, 1997
4. Tawara S, Ikeda F, Maki K, et al.: In vitro activities of a new lipopepride antifungal agent, FK 463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44: 57-62, 2000
5. Ikeda F, Wakai Y, Matsumoto S, et al.: Efficacy of FK 463, a new lipopeptide antifungal agent, in mouse models of disseminated cadidiasis and aspergillosis. Antimicrob Agents Chemother 44: 614-618, 2000
6. Measaki S, Hossain M A, Miyazaki Y, et al.: Efficacy of FK 463, a (1,3)-β-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infections in mice. Antimicrob Agents Chemother 44: 1728-1730, 2000
7. Japanese source. In vitro micafungin 50 (S-1): 94-103, 2002
8. Cantorna M T, Balish E: Mucosal and systemic candidiasis in congenitally immunodeficient mice. Infect Immun 58: 1093-1100, 1990
9. + T-cell-deficient mice for evaluation of antifungal agents. Antimicrob Agents Chemother 40: 1604-1609, 1996
10. Narayanan R, Joyce W A, Greenfield R A: Gastrointestinal candidiasis in a murine model of severe combined immunodeficiency syndrome. Infect Immun 59: 2116-2119, 1991
11. Graybill J R, Vazquez J, Darouiche R O, et al.: Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 104: 33-39, 1998
12. Japanese source. Micafungin 50 (S-1): 104-147, 2002
13. Japanese source. micafungin, in vitro 50 (S-1): 74-79, 2002